The demonstration that tocilizumab (a monoclonal antibody directed against the IL-6 receptor) was able to inhibit the synthesis of IL-8 from triple-negative breast cancer cells, thus blocking both IL-6 and IL-8, which promotes angiogenesis and favor the growth and spread of the disease, suggests that targeting IL-6 means targeting also IL-8, with IL-6 coming first (95). Here, CXCL8 is linked to triple-negative breast carcinoma.